Cellectar Biosciences (CLRB) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 70.7% versus a loss of 89.8%. Over five years, KPTI leads with a -99.3% price change compared with -99.5% for CLRB. Karyopharm Therapeutics is the larger company by market cap ($13.6 million vs $13.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | KPTI |
|---|---|---|
| Share price | $1.40 | $0.60 |
| Market cap | $13.23M | $13.61M |
| 1-day change | -7.28% | -6.98% |
| YTD return | -52.54% | -91.85% |
| 1-year return | -70.71% | -89.83% |
| 5-year return | -99.49% | -99.28% |
| EPS (TTM) | $-3.72 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $10.99 |
| 52-week low | $1.34 | $0.60 |
| Distance from 52-week high | -72.39% | -94.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +721.43% | +1108.33% |
| Average volume | 63.86K | 1.71M |
| Shares outstanding | 9.45M | 22.68M |
| Employees | 11 | 228 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed KPTI by 19.1 percentage points over the past year.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Healthcare · Biotechnology · 11 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Healthcare · Biotechnology · 228 employees
CLRB vs KPTI FAQ
Which is bigger, Cellectar Biosciences or Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) is larger, with a market capitalization of $13.61M compared with $13.23M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or KPTI?
CLRB returned -70.71% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Karyopharm Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.